Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Validation of a Urine-based Assay With Genomic and Epigenomic Markers for Predicting Recurrence During Surveillance for Non-muscle Invasive Bladder Cancer

NCT02969109 is registered in ClinicalTrials.gov with Genomic Health®, Inc. as lead sponsor.

NCT NCT02969109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02969109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Validation of a Urine-based Assay With Genomic and Epigenomic Markers for Predicting Recurrence During Surveillance for Non-muscle Invasive Bladder Cancer
Lead sponsor
Genomic Health®, Inc.
Phase
Observational
Overall status
Completed
Start date
October 31, 2015
Completion date
September 18, 2018
Enrollment
417 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle invasive bladder cancer